Fulcrum Therapeutics Inc. (FULC) Misses Q4 EPS by 1c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q4 EPS of ($0.50), $0.01 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $685 thousand versus the consensus estimate of $1.89 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• JPMorgan Reiterates Underweight Rating on DSM-Firmenich AG (DSFIR:NA), Places on Negative CW
• Grafton Group PLC (GFTU:LN) PT Raised to GBP11.50 at Berenberg